Clinical trials: Transcatheter Arterial Chemoembolization
Hepatocellular Carcinoma Non-resectable
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and tislelizumab in patients with advanced hepatocellullar carcinoma (HCC).
- Trial name
- NCT04599777
- Testing
- TACE combined with sorafenib and tislelizumab
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
SBRT + TACE for Primary Hepatocellular Carcinoma
The purpose of this study is to determine the feasibility and toxicity of combining SBRT and TACE for unresectable HCC and to evaluate the Health Related Quality of Life (HRQL) associated with combined therapy.
- Trial name
- NCT00746655
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Transcatheter Arterial Chemoembolization (TACE)
- Where
- 4 sites in United States
- Sponsor
- University of Pittsburgh
Hepatocellular Carcinoma, Hepatectomy
Hepatectomy With or Without Transcatheter Arterial Chemoembolization for Stage IIIA Hepatocellular Carcinoma
The purpose of this study is to evaluate whether hepatectomy combining with adjuvant transcatheter arterial chemoembolization (TACE) for Stage IIIA hepatocellular carcinoma (HCC) resulting better long-term survival outcome when…
- Conditions
- Hepatocellular Carcinoma, Hepatectomy, Chemoembolization
- Trial name
- NCT00652587
- Testing
- hepatectomy and transcatheter arterial chemoembolization, hepatectomy
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Sun Yat-sen University
Localized Hepatocellular Carcinoma
STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
- Trial name
- NCT03113955
- Testing
- Tandem Microsphere loaded with Epirubicin
- Where
- 10 sites in China
- Volunteers
- 109 people
- Sponsor
- Varian Medical Systems
Hepatocellular Carcinoma Non-resectable
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and sintilimab in patients with unresectable advanced hepatocellullar carcinoma (HCC).
- Trial name
- NCT04599790
- Testing
- TACE combined with lenvatinib and sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Multimodality Therapy for Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels Invasion
The purpose of this study is to compare the effects of different multimodality therapy strategies (initial hepatectomy followed by transcatheter hepatic arterial chemoembolization and/or local regional treatments compare with…
- Trial name
- MDTforHCC (NCT00501813)
- Testing
- Hepatectomy, TACE combined with local regional therapies without hepatectomy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC
The trial is a multicentre, prospective, randomised controlled, unblinded, parallel-group superiority trial of SBRT versus standard TAE/TACE for the curative treatment of inoperable HCC treated with a TAE/TACE incomplete cycle.
- Trial name
- NCT02323360
- Testing
- SBRT, TACE
- Where
- Italy
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Hepatocellular Carcinoma, RFA
Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma
The combination of transcatheter arterial chemoembolization (TACE) with RFA has also reported to be an effective treatment for HCC.
- Conditions
- Hepatocellular Carcinoma, RFA, TACE
- Trial name
- NCT01415063
- Testing
- RFA, TACE-RFA
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Hepatoma
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS).
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
- Trial name
- SOLACE (NCT02460991)
- Testing
- DEB-TACE, Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Boston Scientific Corporation
Neuroendocrine Tumors
Best Therapy for Patients With Neuroendocrine Tumors
A prospective observational study containing three arms comprising different therapeutic measures to treat patients with neuroendocrine tumors in advanced stages.
- Trial name
- BESTTHERAPYNET (NCT00815620)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Zentralklinik Bad Berka
Hepatocellular Carcinoma
Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
The purpose of this study is to determine that systemic chemotherapy is superior to transcatheter arterial chemoembolization in prolonging progression-free survival（PFS） in patients with Advanced Hepatocellular Carcinoma.
- Trial name
- NCT02585479
- Testing
- Pirarubicin, Oxaliplatin, Lipiodol
- Sponsor
- Guangxi Medical University
Liver Neoplasms
Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma
The prognosis of advanced hepatocellular carcinoma is poor. In this study, the eligible patients will be treated by tumor antigen-pulsed autologous dendritic cells and followed by TACE.
- Trial name
- NCT07726329
- Testing
- dendritic cells
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma
Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. It is lack of effective drugs for systemic treatment of HCC.
- Trial name
- NCT03066557
- Testing
- TACE and Apatinib, TACE
- Volunteers
- 80 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Advanced Hepatocellular Carcinoma
Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine whether TAC-101 combined with Transcatheter Arterial Chemoembolization (TACE) is more effective than TACE alone in slowing tumor activity in patients with advanced hepatocellular…
- Trial name
- NCT00667628
- Testing
- TAC-101
- Where
- 29 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Taiho Oncology, Inc.
Hepatocellular Carcinoma
Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma
The aim of this study is to compare the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with the anti-angiogenic targeted drugs and ginsenoside Rg3 versus TACE alone in patients with unresectable…
- Trial name
- NCT04523467
- Testing
- Anti-angiogenic Targeted Drugs, Ginsenoside Rg3, TACE
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma Non-resectable
Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
This is an Open-label, Multicenter, Phase II clinical trial to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combination with Sintilimab (Triple Therapy) sequential radiotherapy…
- Trial name
- NCT06561399
- Testing
- TACE, Lenvatinib combination with Sintilimab sequential radiotherapy
- Where
- 4 sites in China
- Volunteers
- 28 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma
A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignances seen in different regions of the world. The 5-year risk of recurrence of HCC after resection has been reported to be as high as 70%.
- Trial name
- NCT02253511
- Testing
- Cidan capsule
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Zheng Donghai
Carcinoma, Hepatocellular, Neoplastic Cells, Circulating
Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
This study is designed to prospectively evaluate whether post-hepatectomy adjuvant transcatheter arterial chemoembolization (TACE) is effective in reducing early recurrence in HCC patients with preoperative CTC ≥2.
- Trial name
- NCT02631499
- Testing
- TACE, Epirubicin, lipiodol
- Where
- 6 sites in China
- Volunteers
- 256 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma(HCC)
Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR)
Till now, trans-arterial chemoembolization (TACE) is still one of the common modalities in treating hepatocellular carcinoma patients with unresectable intermediate stage.
- Trial name
- TASABR (NCT02921139)
- Testing
- Stereotactic ablative radiotherapy (SABR), Re-Transcatheter arterial chemoembolization (re-TACE)
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Dalin Tzu Chi General Hospital